ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Pharmacoepidemiology of Antiviral Treatment for Congenital Cytomegalovirus in Neonates.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective was to assess the pharmacoepidemiology of ganciclovir and valganciclovir for treatment of congenital cytomegalovirus (cCMV), adverse events, and hearing screen outcomes in infants treated with antiviral therapy.
methodsWe included infants discharged from Pediatrix Medical Group neonatal intensive care units (NICUs) between 2010 and 2020. We calculated the number of infants with cCMV and the proportion treated per year. We identified infants with cCMV treated with antivirals and used logistic regression models to compare adverse events (neutropenia, thrombocytopenia, and hepatic dysfunction) before and during treatment. Hearing screen outcomes were assessed using a logistic regression model as our primary analysis, with further sensitivity analyses to allow for the possibility of endogenous treatment.
resultsA total of 465 infants from 144 sites met our inclusion criteria, of whom 262 received antiviral treatment. From 2010 to 2020, the annual number of infants with cCMV fell by one-third and the proportion of infants receiving antiviral treatment more than doubled. Neutropenia (absolute neutrophil count ANC <1000 μL) was significantly more common among infants receiving antiviral treatment after adjustment for gestational age and postnatal age (OR 3.2, 95% CI: 1.4-7.3). Neither thrombocytopenia nor hepatic dysfunction was associated with treatment. The primary logistic regression analysis and sensitivity analyses indicated that antiviral exposure was associated with elevated risk of hearing screen failure.
conclusionsOur data support previous studies identifying neutropenia as an adverse effect of antiviral treatment. In our cohort of infants with cCMV, treatment was associated with increased likelihood of failed hearing screen; this finding could be a result of unmeasured confounding variables or other limitations of retrospective analysis. Further studies should focus on identifying which infants with cCMV will most likely benefit from treatment, the optimal duration of treatment, and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.